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Background: The grading of recommendation, assessment, development and evaluation (GRADE) approach is
widely implemented in health technology assessment and guideline development organisations throughout the
world. GRADE provides a transparent approach to reaching judgements about the quality of evidence on the
effects of a health care intervention, but is complex and therefore challenging to apply in a consistent manner.
Methods: We developed a checklist to guide the researcher to extract the data required to make a GRADE
assessment. We applied the checklist to 29 meta-analyses of randomised controlled trials on the effectiveness of
health care interventions. Two reviewers used the checklist for each paper and used these data to rate the quality
of evidence for a particular outcome.
Results: For most (70%) checklist items, there was good agreement between reviewers. The main problems were
for items relating to indirectness where considerable judgement is required.
Conclusions: There was consistent agreement between reviewers on most items in the checklist. The use of this
checklist may be an aid to improving the consistency and reproducibility of GRADE assessments, particularly for
inexperienced users or in rapid reviews without the resources to conduct assessments by two researchers
independently.
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The grading of recommendation, assessment, develop-
ment and evaluation (GRADE) approach provides guid-
ance on rating the quality of research evidence in health
care [1]. This approach has been widely implemented by
organisations such as the World Health Organization,
Cochrane Collaboration, Agency for Healthcare Research
and Quality (USA) and National Institute of Health and
Care Excellence (UK).
The GRADE approach is comprehensively described
in an online manual (freely available for download with
the GRADEpro software at http://tech.cochrane.org/rev-
man/gradepro). This is summarised in a series of papers* Correspondence: nick.meader@york.ac.uk
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unless otherwise stated.published in the BMJ in 2008 [2] and is also explained in
a more detailed collection of papers in the Journal of
Clinical Epidemiology (JCE) beginning in 2011 [1,3-15].
The GRADE approach is used to assess the quality of
evidence for a specific outcome across studies. It applies
most directly to a meta-analysis undertaken in the
context of a systematic review but can be applied also to
individual studies or non-quantitative syntheses when
meta-analyses are not available. Evidence from rando-
mised controlled trials (RCTs) begins as high-quality evi-
dence but can be downgraded according to five factors:
risk of bias, inconsistency, indirectness, imprecision and
publication bias. Evidence from non-randomised studies
begins as low-quality evidence, but their rating can be
upgraded (provided no other limitations have been iden-
tified according to the five factors). Upgrading occurs for
three primary reasons: large magnitude of effect, evidencel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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taken into account. After the process of downgrading or
upgrading, the quality of the evidence for each outcome
ends up rated as high, moderate, low or very low. For the
purposes of this paper, we will focus on the application of
GRADE to meta-analyses of RCTs.
A major advantage of GRADE is that it leads to more
transparent judgements about the quality of evidence
[16]. The five key specific factors that may lead to down-
grading the quality of evidence (and the need to state
reasons for each downgrade) help to provide a clear ra-
tionale for such judgements. In addition, there is detailed
written guidance from the GRADE working group for
making these judgements. A further advantage of the
broader GRADE framework is its ability to indicate the
strength of recommendations based on the evidence.
However, a challenge to this extensive guidance is the
complexity of the approach. There are substantial con-
ceptual challenges when an organisation moves from
previous methods of assessing overall study quality to
implementing GRADE [16]. For example, it may be diffi-
cult for a researcher (particularly if they have limited ex-
perience of systematic reviews and/or GRADE) to
remember and apply this guidance in a consistent man-
ner (both within assessments as an individual, and be-
tween researchers in the same team) in the often time-
pressured environment of conducting systematic reviews
and guideline development.
Two recent empirical studies have examined the
consistency of GRADE assessments. Hartling et al. [17]
found poor-to-moderate agreement (based on kappa
values) between researchers experienced in systematic
review methods on rating quality of evidence. The
GRADE working group [18] recently conducted an
evaluation of consistency which was stratified by level of
experience of the raters (members of the GRADE work-
ing group, students on the health research methodology
programme at McMaster University). Inter-rater agree-
ment was moderate when comparing individual ratings
conducted independently by two researchers for both
experienced members of the GRADE working group and
for members of the student group. Inter-rater agreement
was higher for members of the GRADE working group,
when ratings were based on two individuals working in-
dependently who then reached a consensus judgement,
then compared this judgement with another pair using
the same consensus methods. Both studies suggest that
GRADE ratings may not result in sufficient inter-rater
agreement if conducted only by one assessor. Two expe-
rienced reviewers conducting a GRADE assessment
in duplicate appears to result in acceptable agreement.
However, this is less clear for inexperienced users of
GRADE [18]. Therefore, further resources may improve
consistency in conducting GRADE assessments by reviewerswith less experience or for those with insufficient time
and resources to conduct assessments by two reviewers
independently.
We developed a checklist for evaluating meta-analyses
of RCTs for the purpose of informing a GRADE assess-
ment. The checklist covers the main determinants for
each of the five factors (risk of bias, inconsistency, indir-
ectness, imprecision, publication bias) that can lead to a
downgrading of quality in the GRADE system. In this
paper, we describe the development of the checklist and
report on agreement between independent raters on
each of the constituent items.
Methods
Developing the checklist
Two authors (GS, NM) drew a logic model which aimed
to represent the GRADE assessment process (see Figure 1).
The logic model comprises nodes for the various char-
acteristics and properties of the evidence, connected
with arrows to indicate how these attributes impact on
each other. Population of the model was based on arti-
cles written by the GRADE working group with par-
ticular emphasis on the most recent series of articles in
the JCE [1,3-15].
From this logic model, we developed a checklist of
questions to extract the data required for conducting a
GRADE assessment (see Figure 1). The full checklist ap-
pears in Additional file 1. Where possible, all questions
were derived as directly as possible from literature pro-
duced by the GRADE working group. However, where
specific guidance was lacking, some of the questions in-
cluded our value judgements (e.g. what constitutes a
low, medium or high value of I2; or the extent to which
confidence intervals overlap; or what constitutes a high
dropout rate).
Questions about study limitations (risk of bias) were
based on items in the Cochrane risk of bias tool [19] as
suggested by the GRADE working group [6]. They are to
be answered in relation to the majority of the aggregated
evidence in the meta-analysis rather than to individual
studies. Questions about inconsistency were based pri-
marily on visual assessment of forest plots and the statis-
tical quantification of heterogeneity based on I2 and Q
statistics. This includes assessments of subgroups (par-
ticularly those defined a priori) that appear to explain
the inconsistency.
Indirectness items included questions on the applic-
ability of the population, intervention, comparator and
outcome (whether a surrogate or not, and whether
follow-up time was sufficient) based on the majority of
the aggregated evidence in the meta-analysis. The check-
list does not specifically address reviews using network
meta-analysis (as there is not currently any published
guidance on this). However, the checklist did consider
Figure 1 Logic model for developing the checklist based on GRADE criteria. A logic model illustrating how the checklist items relate to the
risk of bias, inconsistency, indirectness, imprecision and publication bias domains in GRADE.
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made between interventions based on pairwise meta-
analysis.
Imprecision was addressed through items relating to the
width of the confidence interval and sample size. When
judging the width of the confidence interval, GRADE rec-
ommends that reviewers use a clinical decision threshold
to assess whether the imprecision is clinically meaningful
[8]. We did not explicitly build this into the checklist, al-
though the initial question about whether the estimate is
consistent with benefit and harm might be interpreted in
relation to a minimally important difference.
Questions about publication bias addressed com-
prehensiveness of the search strategy, whether included
studies had industry influence and funnel plot asym-
metry and whether there was evidence of discrepancies
between published and unpublished trials.
We focused specifically on meta-analyses of RCTs.
Therefore, we did not include factors to upgrade the evi-
dence (magnitude of effect, dose-response relationship,
adjusting for known confounding) as these are recom-
mended for use only in the context of systematic reviews
of non-randomised studies where downgrading was not
required for any of the five potential factors.
Initial piloting of the checklist
We conducted two phases of initial piloting of these
questions. First, the wider project team applied the draft
checklist independently to five systematic reviews andthen met to discuss their assessments and any difficulties
they experienced. Second, a set of 15 systematic reviews
was assessed by two reviewers independently to identify
any further potential difficulties. Both phases led to
some refining of the instrument. One of the challenges
identified by the team in the second phase was that the
response ‘yes’ referred to something positive (e.g. was
the sequence generation randomised?) in some items
and negative in others (e.g. was there selective reporting?).
Several reviewers suggested it would be more straightfor-
ward to use the checklist if all questions were worded so
that ‘yes’ always referred to a positive feature of the quality
of evidence and ‘no’ to something negative (where yes and
no responses were required). Therefore, we included this
modification in the main validation of the checklist.
External validation of the checklist
Following the development and initial piloting of the
checklist, we conducted a more formal evaluation of its
inter-rater agreement. We examined 29 systematic re-
views containing a meta-analysis of RCTs included in
the Database of Abstracts of Reviews of Effects (DARE)
[20-48] (Table 1). One author (NM) selected the reviews
to ensure variety both in terms of reporting and reliability
based on an informal assessment of the systematic re-
views. Papers were selected to ensure a diverse range of
reviews from a variety of disease areas including cardi-
ology, diabetes, chronic obstructive pulmonary disease,
neurological conditions (dementia, stroke, Parkinson's
Table 1 Brief summary of systematic reviews included in pilot evaluation
Author Title Intervention type Topic area
AHRQ [20] Comparative effectiveness review 86: treatment for restless legs syndrome Pharmacological Neurology
Amato et al. [21] Methadone at tapered doses for the management of opioid withdrawal Pharmacological Tobacco, drugs
and alcohol
Andrews et al. [22] Interventions to influence consulting and antibiotic use for acute respiratory tract
infections in children: a systematic review and meta-analysis
Psychosocial Respiratory
infections
Andrews et al. [23] Computer therapy for the anxiety and depressive disorders is effective,




Birks [24] Cholinesterase inhibitors for Alzheimer's disease Pharmacological Neurology
Cape et al. [25] Brief psychological therapies for anxiety and depression in primary care: meta-
analysis and meta-regression
Psychological Mental health
Chen et al. [26] Gefitinib or erlotinib as maintenance therapy in patients with advanced stage
non-small cell lung cancer
Pharmacological Cancer
Cipriani et al. [27] Escitalopram versus other antidepressive agents for depression Pharmacological Mental health
Eaton et al. [28] Meta-analysis of single-session behavioural interventions to prevent sexually
transmitted infections: implications for bundling prevention packages
Psychosocial Infectious disease




Eyding et al. [30] Reboxetine for acute treatment of major depression: systematic review and
meta-analysis of published and unpublished placebo and selective serotonin
reuptake inhibitor controlled trials
Pharmacological Mental health
Gould et al. [31] Efficacy of cognitive behavioural therapy for anxiety disorders in older people:
a meta-analysis and meta-regression of randomized controlled trials
Psychological Mental health
Harkness et al. [32] Identifying psychosocial interventions that improve both physical and mental
health in patients with diabetes
Psychosocial Mental health and
endocrine and
metabolic
Huedo-Medina et al. [33] Efficacy of HIV prevention interventions in Latin American and Caribbean nations
1995-2008: a meta-analysis
Psychosocial Infectious disease
Johnston et al. [34] Probiotics for the prevention of Clostridium difficile-associated diarrhea: a
systematic review and meta-analysis
Probiotics Infectious disease
Makani et al. [35] Efficacy and safety of dual blockade of the rennin-angiotensin system:
meta-analysis of randomised trials
Pharmacological Heart and
circulation
Minns Lowe et al. [36] Effectiveness of physiotherapy exercise after knee arthroplasty for osteoarthritis:
systematic review and meta-analysis of randomised controlled trials
Physical Rheumatology
Nelson et al. [37] A systematic review and meta-analysis of placebo-controlled antidepressant
studies in people with depression and dementia
Pharmacological Mental health and
neurology
Perez-Mana et al. [38] Efficacy of indirect dopamine agonists for psychostimulant dependence: a
systematic review and meta-analysis of randomised controlled trials
Pharmacological Tobacco, drugs
and alcohol
Pinto et al. [39] Epidural corticosteroid injections in the management of sciatica: a systematic
review and meta-analysis
Pharmacological Rheumatology
Preiss et al. [40] Lipid-modifying therapies and risk of pancreatitis: a meta-analysis Pharmacological Heart and
circulation
Rayner et al. [41] Antidepressants for depression in physically ill people Pharmacological Mental health
Skapinakis et al. [42] Efficacy and acceptability of selective serotonin reuptake inhibitors for the
treatment of depression in Parkinson's disease: a systematic review and
meta-analysis of randomized controlled trials
Pharmacological Mental health and
neurology
Soomro et al. [43] Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive
compulsive disorder
Pharmacological Mental health




Wardlaw et al. [45] Thrombolysis for acute ischaemic stroke Pharmacological Neurology
Ye et al. [46] Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase
III randomized controlled trials
Pharmacological Cancer
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Table 1 Brief summary of systematic reviews included in pilot evaluation (Continued)
Zhang et al. [47] Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in
metastatic colorectal cancer: meta-analysis of randomized controlled trials
Pharmacological Cancer
Zhong [48] Chemotherapy plus best supportive care versus best supportive care in patients
with non-small cell lung cancer: a meta-analysis of randomized controlled trials
Pharmacological Cancer
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cancer, metastatic colorectal cancer) and prevention of
pancreatitis, osteoarthritis, restless legs syndrome and
sciatica. In addition, reviews on substance misuse (opioid
detoxification, psychostimulant dependence), mental health
(depression, anxiety, obsessive compulsive disorder,
attention deficit hyperactivity disorder) and HIV pre-
vention were also included. Pharmacological and non-
pharmacological interventions were included.
The checklist was used by two reviewers independently
for all selected reviews. For each review, one author (NM)
developed a review question in terms of the population,
intervention, comparison and outcome (PICO) of interest.
One critical outcome (the primary outcome) was selected
for assessment for each review. GRADE recommends a
maximum of nine outcomes, but we limited it to one out-
come for the purposes of this study to enable reviewers to
assess a wider sample of reviews.
Reviewers based their assessments on the information
reported in the paper relating to the systematic review
and did not seek to obtain information from the original
reports of included RCTs (other than for evidence of in-
dustry involvement which was rarely reported in system-
atic reviews and therefore original papers of the largest
studies in the meta-analysis were checked).
We calculated a weighted kappa statistic with 95%
confidence interval (CI) for each item of the checklist. We
interpreted the coefficients according to the following
guidelines: below chance was considered poor; 0.01 to 0.20
slight agreement; 0.21 to 0.40 fair agreement; 0.41 to 0.60
moderate agreement; 0.61 to 0.80 substantial agreement;
and 0.81 to 1 almost perfect agreement [49]. Each reviewer
recorded the time spent conducting an assessment, and
from these data, we summarised these to estimate the
likely resource implications of using this approach.
Experience of reviewers
Seven reviewers from the Centre for Reviews and Dissemin-
ation (CRD) participated in the checklist assessments. CRD
specialises in conducting, critically appraising and develop-
ing methods for evidence syntheses and systematic reviews.
Years of systematic review experience among participants
ranged from 2 to 10. Although six reviewers had no formal
training or experience using GRADE, all were experienced
in critical appraisal and validity assessment (of both primary
studies and systematic reviews), for example, the Cochrane
risk of bias tool and quality assessment according to criteria
developed by CRD.Two authors (GS, NM) provided informal GRADE
training during the course of the study and provided
guidance on completing the checklist.
Results
Judgements for each of the checklist items
Measures of agreement for all specific items in the
checklist are given in Table 2. For most of the items de-
signed to examine risk of bias, agreement was found to
be either almost perfect or substantial. For one item, de-
signed to measure attrition bias, agreement was moderate.
For items concerning no other bias and selective reporting,
level of agreement was relatively low.
For all items on imprecision, there was almost perfect
agreement which reflects the fact that less judgement is
needed for these items, and therefore, a high level of
agreement would be expected.
Four of the five items on inconsistency had almost per-
fect or substantial agreement. The item on the extent of
overlap of confidence intervals was associated with mod-
erate agreement.
Two of the items on indirectness (applicability of popu-
lation and applicability of intervention) did not perform
well, and the consistency was below chance. For two of
the items (use of surrogate outcome and direct compari-
sons), agreement was almost perfect, and for one item
moderate (sufficiency of follow-up time for outcome).
For five out of six items on publication bias, there
was substantial or almost perfect agreement. Only fair
agreement was found on the item for searching grey
literature.
Time required for conducting assessments
The median time to conduct the assessment was 30 min
(range = 15–90 min). Informal assessment suggested that
years of experience of reviewers and complexity of the
review appeared to be the main factors impacting on
variability of time taken to complete assessment.
Reviewers' feedback suggested that it was relatively
straightforward to use the checklist despite almost all re-
viewers having no prior formal training or experience
using GRADE.
Discussion
Some of the main difficulties in applying the GRADE
system are the complexity and cognitive demands of
the approach and the potential lack of reproducibility
of the judgements made. Our proposed checklist helps
Table 2 Agreement for all checklist items
Item Kappa (95% CI) Magnitude of agreement
Risk of bias
Was random sequence generation used (i.e. no potential for selection bias)? 0.89 (0.69 to 1) Almost perfect
Was allocation concealment used (i.e. no potential for selection bias)? 0.69 (0.29 to 1) Substantial
Was there blinding of participants and personnel (i.e. no potential for performance bias)? 0.71 (0.41 to 1) Substantial
Was there blinding of outcome assessment (i.e. no potential for detection bias)? 0.98 (0.67 to 1) Almost perfect
Was an objective outcome used? 1 Almost perfect
Were more than (80%)a of participants enrolled in trials included in the analysis? (i.e. no potential
attrition bias)
0.44 (0.07 to 0.81) Moderate
Were data reported consistently for the outcome of interest (i.e. no potential selective reporting)?
(no potential reporting bias)
0.25 (0 to 0.61) Fair
No other biases reported? (no potential of other bias) 0.20 (0 to 0.62) Slight
Did the trials end as scheduled (i.e. not stopped early)? 1 Almost perfect
Inconsistency
Point estimates did not vary widely? (i.e. no clinical meaningful inconsistency) 0.65 (0.37 to 0.93) Substantial
To what extent do confidence intervals overlap? 0.50 (0.17 to 0.77) Moderate
Was the direction of effect consistent? 1 Almost perfect
What was the magnitude of statistical heterogeneity (as measured by I2)? 1 Almost perfect
Was the test for heterogeneity statistically significant (p < 0.1)? 1 Almost perfect
Indirectness
Were the populations in included studies applicable to the target population? Below chance Poor
Were the interventions in included studies applicable to target intervention? Below chance Poor
Was the included outcome not a surrogate outcome? 1 Almost perfect
Was the outcome timeframe sufficient? 0.47 (0 to 1) Moderate
Were the conclusions based on direct comparisons? 1 Almost perfect
Imprecision
Was the confidence interval for the pooled estimate not consistent with benefit and harm? 1 Almost perfect
What was the magnitude of the median sample size? 1 Almost perfect
What was the magnitude of the number of included studies? 1 Almost perfect
Was the outcome a common event? (e.g. occurs more than 1/100)a 1 Almost perfect
Was there no evidence of serious harm associated with treatment? 0.89 (0.67 to 1) Almost perfect
Publication bias
Did the authors conduct a comprehensive search? 0.65 (0 to 1) Substantial
Did the authors search for grey literature? 0.26 (0 to 0.67) Fair
Authors did not apply restrictions to study selection on the basis of language? 0.74 (0.45 to 1) Substantial
There was no industry influence on studies included in the review? 0.71 (0.45 to 0.98) Substantial
There was no evidence of funnel plot asymmetry? 0.62 (0.35 to 0.89) Substantial
There was no discrepancy in findings between published and unpublished trials? 1 Almost perfect
aThese thresholds can be replaced with different ones based on the context of the particular review.
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needed for a GRADE assessment in a repeatable man-
ner. In addition, it increases transparency because the
items used to make the assessment are clearly identified.
For most checklist items (70%), there was substantial
agreement or better, suggesting that most of the data re-
quired for a GRADE assessment can be extracted in a
repeatable manner.However, some problems were identified for checklist
items relating to indirectness. There was a lack of agree-
ment for most of these items, although there was good
agreement on surrogate outcomes. This reflects GRADE
guidance which acknowledges that considerable judgement
is needed when considering the applicability with regard to
populations and interventions [10]. In addition, it is likely
that given the wide scope of the reviews being quality
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target population and intervention. As assessments were
conducted independently, it was not possible to discuss
how to apply criteria for assessing indirectness (or consult
with advisors with expertise in the subject area), which is
common practice when working in a team of reviewers.
A potential limitation of this study is that we con-
ducted the GRADE assessments on published reviews,
therefore basing our judgement on the data reported in
these reviews rather than as part of the process of con-
ducting a systematic review. It is possible agreement
would either increase or decrease if we used the latter
approach. However, our approach reflects the reality of
guideline development and of conducting overviews of
reviews where evidence from existing systematic reviews
will often be utilised to inform conclusions and/or rec-
ommendations. It is also consistent with the methods
used in a previous evaluation of the inter-rater agree-
ment for GRADE assessments [18].
A further potential limitation is that the systematic re-
views we assessed were not randomly selected. However,
for the purposes of this study, we were not aiming to
provide a random sample of all systematic reviews. In-
stead, we wanted to ensure that reviews from a variety
of disease areas and using different types of interven-
tions were examined during the assessment of the per-
formance of the checklist.
The checklist only includes criteria relating to system-
atic reviews that include meta-analyses of RCTs. Of
course, the GRADE approach can be applied to non-
randomised studies and also synthesis techniques other
than meta-analysis. Further work is needed to adapt and
validate this checklist for such reviews. A further pos-
sible limitation was that effort to make all ‘yes’ responses
to questions reflect low bias may have resulted in awk-
ward wording (e.g. use of double negatives) for some
items. This may have reduced the user-friendliness of the
checklist and potentially reduced inter-rater agreement.
While aiming to reduce some of the complexity
of conducting GRADE assessments, it is important to
note that reviewers still need to develop clearly defined
review questions (including the selection of critical or
important outcomes) before completing the checklist. In
addition, using the checklist still requires the reviewer
to make important value judgements. For example, as
noted above, considerable judgement is needed to assess
the applicability of populations, interventions and com-
parisons for a particular review question. Similarly, re-
viewers will need to develop thresholds to assess, for
example, whether the width of the confidence interval
for a pooled estimate (for questions on imprecision) and
variability in study estimates (for questions on inconsist-
ency) included in the meta-analysis constitute clinically
meaningful threats to validity.In addition, the issue of improving repeatability of
GRADE assessments that we address in this paper is one
among many challenges in the use of GRADE. One of
these other challenges is that of how to decide whether
to downgrade by none, one or two levels for issues iden-
tified in one of the five GRADE domains. Considerable
guidance is available from GRADE on how these differ-
ent factors should be weighted, and scenarios provided
where a combination of factors should likely lead to a
downgrade by one or two levels. Our checklist provides
added structure for the information to inform this
decision but does not necessarily highlight when there is
sufficient evidence to justify any particular degree of
downgrading.
To this end, we have developed a semi-automated
quality assessment tool (SAQAT) which is a Bayesian
network model that uses responses to the checklist
questions to produce GRADE assessments. Although
semi-automated approaches have not been widely used
in critical appraisal of systematic reviews, they may offer
an alternative for reviewers who struggle with the com-
plexity of GRADE. Manuscripts about the SAQAT and its
performance in practice are currently in development.
Conclusions
In conclusion, experienced systematic reviewers but with
little or no experience of conducting GRADE assessments
appear to be able to answer our checklist of questions
in a broadly consistent and reproducible manner when
assessing the quality of evidence for meta-analyses
of RCTs. Further work is needed to improve agree-
ment on judgements relating to applicability of inter-
ventions and populations (as factors to consider within
indirectness).
Use of our checklist is most likely to benefit those with
limited experience of using GRADE. However, given the
complexity of GRADE, we think the checklist may act as
a helpful reminder for experienced users of the key fac-
tors to consider for each of the five GRADE domains
(risk of bias, imprecision, inconsistency, indirectness and
publication bias). Our checklist may offer improvements
in efficiency and time and therefore may be beneficial
when used in the context of a rapid review. For example,
we found that inexperienced users of GRADE were able
to complete an assessment in a median of 30 min.
Next steps include the need to pilot the use of this
checklist when conducting systematic reviews and/or
during guideline development and assess whether this
results in more consistent judgements when conducting
a GRADE assessment. It would also be important to as-
sess further the utility of using the checklist for different
review questions and disease areas, and the extent to
which it might need to be adapted. We particularly en-
courage researchers and health technology assessment
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GRADE to pilot our tool and provide us with feedback to
inform further development.
Additional files
Additional file 1: Checklist for the quality assessment tool. The
checklist covers the main determinants for each of the five factors: risk of
bias, inconsistency, indirectness, imprecision and publication bias.
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